The MET oncogene as a therapeutical target in cancer invasive growth

Paolo Luraghi, Florian Schelter, Achim Krüger, Carla Boccaccio

Research output: Contribution to journalArticlepeer-review


The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF) regulates invasive growth, a genetic program that associates control of cell proliferation with invasion of the extracellular matrix and protection from apoptosis. Physiologically, invasive growth takes place during embryonic development, and, in post-natal life, in wound healing and regeneration of several tissues. The MET oncogene is overexpressed and/or genetically mutated in many tumors, thereby sustaining pathological invasive growth, a prerequisite for metastasis. MET is the subject of intense research as a target for small molecule kinase inhibitors and, together with its ligand HGF, for inhibitory antibodies.The tight interplay of MET with the protease network has unveiled mechanisms to be exploited to achieve effective inhibition of invasive growth.

Original languageEnglish
Article numberArticle 164
JournalFrontiers in Pharmacology
Volume3 SEP
Publication statusPublished - 2012


  • Antibody
  • Invasion
  • MET oncogene
  • Metastasis
  • Microenvironment
  • Proteases
  • Small molecule kinase inhibitors
  • Targeted therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'The MET oncogene as a therapeutical target in cancer invasive growth'. Together they form a unique fingerprint.

Cite this